Previous 10 | Next 10 |
REHOVOT, Israel and WILMINGTON, Del., June 02, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in gene...
If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...
Goldman Sachs has increased the price target on SpringWorks Therapeutics (NASDAQ:SWTX) on Tuesday after the clinical-stage biotech reported positive data from its Phase 3 trial for lead candidate nirogacestat in adults with progressing desmoid tumors. SpringWorks (SWTX) said that the 142-pati...
1Q22 Reported With Clinical Updates. Ayala Pharmaceuticals reported a 1Q22 loss of $10.0 million or $(0.66) per share. Interim results from the Phase 2/3 RINGSIDE trial testing AL102 in desmoid tumors are expected to be announced in mid-2022, unchanged from previous guidance. The company also ...
Ayala Pharmaceuticals press release (NASDAQ:AYLA): Q1 GAAP EPS of -$0.66 beats by $0.02. Revenue of $0.37M (-61.9% Y/Y) misses by $0.46M. For further details see: Ayala Pharmaceuticals GAAP EPS of -$0.66 beats by $0.02, revenue of $0.37M misses by $0.46M
REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in ge...
REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in ...
Ayala Reported FY2021 Within Expectations Ayala Reported FY2021 loss of $40.3 million or $(2.80) per share. This compares with our estimate of a loss of $40.9 million or $(3.00) per share, as both R&D and General Expenses were slightly below our estimates. Cash balance on December 31 was $...
Ayala Pharmaceuticals press release (NASDAQ:AYLA): FY GAAP EPS of -$2.80. Revenue of $3.5M (-5.7% Y/Y). For further details see: Ayala Pharmaceuticals GAAP EPS of -$2.80, revenue of $3.5M
REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Ayala or the Company) (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggre...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...